Objective: Use of soft ultrasonographic markers during routine prenatal ultrasonography (USG) may be used for the screening of aneuploidy in the low-risk population. The aim of this study was to evaluate the acceptance of an invasive test for prenatal diagnosis and to assess the role of various factors in the decision-making regarding an invasive test when confronted with risk for aneuploidy after a soft marker is detected on routine antenatal ultrasonogram.
Introduction
Ultrasonography (USG) for fetal well-being and prenatal diagnosis of malformation has become an important part of obstetric care. In addition to malformations, many ultrasonographic markers have been identified as risk factors for chromosomal abnormalities. These ultrasonographic markers, namely nuchal fold thickening, echogenic cardiac focus, echogenic bowel, mild ventriculomegaly and nasal bone hypoplasia are associated with increased risk of aneuploidy of varying magnitude. 1, 2 Identification of any of these findings requires further counseling and possible referral to a prenatal diagnostic center with the provision of an option of an invasive test for fetal karyotyping. 1 Other sonographic markers, such as choroid plexus cyst, renal pyelectasis, short femur and single umbilical artery are not known to be associated with a significant risk of chromosomal anomalies, particularly if present in isolation. Thus, amniocentesis is not indicated for these findings alone. 3 However, presence of any of these markers certainly calls for a careful search for other malformations or other risk factors for chromosomal or genetic abnormalities.
On ultrasonographic examination done routinely for malformation scanning and/or other obstetric reasons, these soft markers can be detected. Since the general population in India is not aware of chromosomal disorders and the background risk remains low, counseling after detection of soft marker is challenging. As the triple test (maternal serum a-fetoprotein, estriol, and b-human chorionic gonadotrophin), which is the second trimester serum screening test for aneuploidy, is not routinely offered to all pregnant women in India, these soft markers play an important role in screening for aneuploidy in the low-risk population.
The definitive test of fetal karyotyping requires amniocentesis, an invasive procedure associated with a small risk (0.5%) of procedure-related abortion. Not every family with an ultrasonographic marker opts for amniocentesis. This study examined the uptake of an invasive diagnostic test (amniocentesis) after detection of soft marker on USG and studied role of various factors, like maternal age, obstetric history, gestational age and the marker detected in the acceptance or rejection of an invasive test, for fetal karyotype.
Methods

Study subjects
A total of 939 women were referred to our center, which is a Department of Medical Genetics at a tertiary care research institute, for an antenatal ultrasound from January 2004 to April 2006. The women were referred by obstetricians for routine USG and for various reasons such as a previous child with a congenital malformation, stillbirth, or a genetic disorder, or a past history of recurrent spontaneous abortions. Women were also referred for confirmation of findings after detection of a soft marker on the routine antenatal USG. Women who had previously undergone amniocentesis or chorionic villus sampling, who had a fetus with a major congenital malformation or who had another risk factor like positive maternal serum screening test were excluded from the study. Women with a twin gestation were also excluded to maintain a homogeneous population. Additionally, women with a previous child with a chromosomal abnormality were also excluded, as they were offered invasive prenatal diagnosis irrespective of the USG findings. One clinical geneticist trained in USG and experienced in genetic counseling did the USG and counseling of all cases. The machine used was Flexus, SSD 1100 from Aloka Co. Ltd. (Mitaka-shi, Tokyo, Japan).
All women found to have a soft marker were explained about the likelihood of having aneuploidy (Table 1 ) and the use of amniocentesis for fetal karyotyping. The markers were grouped into three groups, roughly based on the magnitude of the risk based on the likelihood ratios and not on the individualized risks: (A) High risk of aneuploidy: increased nuchal thickening, mild ventriculomegaly and nasal bone hypoplasia. (B) Moderate risk: echogenic focus in heart and echogenic bowel. (C) Low risk: choroid plexus cyst, single umbilical artery, short humerus/femur and renal pyelectasis present in isolation. The mother's age, the gestational age and the information regarding obstetric history were recorded. Cases with previous spontaneous abortions, stillbirths or neonatal deaths were grouped as bad obstetric history.
Counseling
The risk of aneuploidy associated with USG soft markers is an evolving field and many studies with varying number of cases with one or multiple markers are still being published. Though there is consensus about the utility of nuchal thickening for detection of aneuploidy, there are varying views about the magnitude of aneuploidy risk associated with other markers.
3-9,10 -12 Age related prior risk was converted to percent risk by using likelihood ratios given in the literature. The risk in percent form is easy for the families to understand and interpret. Nuchal fold thickness, 3 nasal bone hypoplasia 4 and mild ventriculomegaly 5 in isolation have a higher risk of aneuploidy compared to other markers in isolation. The relative risk for nuchal fold thickening of >4, >5, >6 mm is 18, 28, 36 respectively. 3 The risk of chromosomal abnormalities associated with isolated ventriculomegaly is reported to be 4%. 5 Significant chromosomal anomalies (3.5%) are reported in association with echogenic bowel in a large French collaborative study. 10 Likelihood ratios reported for aneuploidy in echogenic bowel vary from 3 to 6.7. 2, 8, 11 The risk of aneuploidy in fetuses with echogenic foci in heart as an isolated finding was calculated in a prospective study as 1% indicating that amniocentesis is warranted in these cases. 13 Benacerraf 14 suggested that the rate of chromosomal anomalies in fetuses with isolated echogenic focus in heart is four times higher than that related to the specific maternal age. Winter et al. 15 in a study of 3303 fetuses, 162 with echogenic foci gave likelihood ratio of 4.2. Nyberg et al. 11 have given likelihood ratio of echogenic focus as 1.8. Recent studies say that there is no increased risk of Down's syndrome in low-risk women with echogenic foci. 16, 17 The risk of aneuploidy is not increased with isolated choroids plexus cyst. 3, 9 However, the pregnant women detected to have choroid plexus cyst in the fetus were also informed that USG may not be able to detect all associated malformations, and rarely a fetus with isolated choroid plexus cyst may have chromosomal abnormality. Same is true for single umbilical artery. Women with fetus with single umbilical artery were counseled that the risk for chromosomal abnormality is not significant and amniocentesis for karyotyping is not indicated. For renal pylectasis, the data are unclear and the relative risk reported varies from 1.5 6,11 to 3.9 3 times for Down's syndrome. Risk of aneuploidy based on the mother's age and likelihood ratios for the marker detected was given to the pregnant women and their families. It was explained that presence of choroid plexus cyst, renal pyelectasis and short femur are not associated with high risk of chromosomal abnormalities, if present in isolation, and amniocentesis for fetal karyotyping is not indicated. Presence of single umbilical artery is also not included as a soft marker in the literature, but we have included it as these cases were referred by obstetricians for karyotyping. The presence of any of these calls for a careful USG to look for other major or minor malformations. The risk of aneuploidy was explained in comparison with background population risk and age-specific risk. Sharing of this information was considered to be essential, as it is not ethically tenable to withhold information obtained during the test. In many cases, the patient was herself aware of these findings, as she had been referred for the same findings. A report of USG findings along with written material explaining the various abnormalities and their outcome was given to the couple. The clinical geneticist, who also did the USG, counseled them, and information regarding the invasive procedure and the 0.5% risk of abortion following the procedure was also given. Their queries were answered and a written consent was obtained if the woman agreed for the procedure.
Statistical analysis
The maternal characteristics like maternal age, gestational age and the obstetric history at time of presentation were the variables taken as factors associated with invasive testing. The differences between the groups (those who agreed for amniocentesis and those who disagreed) were compared using w 2 and Fisher's exact test. P<0.05 was considered as statistically significant. SPSS version 13.0 was used for analysis of statistical data.
Results
Of the 939 women referred to our center for an antenatal ultrasound, soft markers for chromosomal abnormality were detected in 54 women (5.75%). Four women were excluded, as they had undergone a first trimester prenatal diagnosis for nonchromosomal disorders (previous child with thalassemia major, spinal muscular atrophy and hemophilia) and karyotypes done from chorionic villi were reported as normal. Genetic counseling was offered to 50 couples who were diagnosed as having soft markers on USG. Out of the 50 women, 29 were referred for a routine ultrasound; 11 were sent for confirmation of the soft marker, after detecting a finding on routine USG; 10 women were referred as they had a history of a previous child with malformation. Of these, 20 (40%) agreed to undergo amniocentesis for fetal karyotyping.
The number of cases with each type of soft marker and amniocentesis done among each group is shown in Table 2 . The numbers of cases for individual marker were low, and hence the acceptance of amniocentesis for each marker could not be compared. But among the three risk groups, the acceptance of amniocentesis was 44% for group A, 37% for group B and 44% for group C, and the difference was not statistically significant.
Echogenic focus in heart was the commonest soft marker, detected in 16 cases, followed by echogenic bowel in 11 cases. Increased nuchal fold thickness (in isolation or in association with other marker) was seen in nine cases and acceptance for amniocentesis was maximum for this marker (78%) compared to all other markers taken together (35%). This difference was statistically significant (P ¼ 0.02, (relative risk) RR ¼ 2.4 with 95% CI ¼ 1.31 to 4.47). All the ultrasonographic examinations were done in second trimester; hence, there was only one case of nasal bone hypoplasia.
A single marker was detected in 43 cases, and of these, 13 (30%) opted for amniocentesis. Nine cases were detected with two or more markers; and of them, five cases (71%) with two markers and both the cases (100%) with three markers agreed for amniocentesis. The number of cases with two or more markers was few, but the acceptance of amniocentesis appears to increase with more number of markers.
The distribution according to maternal age, gestational age and obstetric history and acceptance of procedure is shown in Table 3 . In our study, 86% women were less than 35 years, while 14% women were more than 35 years of age. The median age at referral was 28 years. Among women less than 35 years, almost 40% agreed for amniocentesis, while in those above 35 years of age, 43% agreed. Thus, there was no significant statistical difference (P ¼ 1.00) in acceptance of amniocentesis, depending on maternal age. Invasive tests on detecting soft markers on USG S Sharda and SR Phadke
The mean age of gestation at reference was 20 weeks. Reference for an anomaly scan was done as late as 32 weeks of gestation. Among women of more than 24 weeks gestation, 38.5% agreed for an invasive test, and this was not statistically different (P ¼ 0.84) from women of less than 24 weeks gestational age (40.5%).
Depending on the obstetric history, there was no statistical difference in the uptake as far as the parity was concerned. The uptake was comparable between primigravida (33%) and multiparous women (41%) (P ¼ 0.90). Almost 50% of women with bad obstetric history (n ¼ 15), while 37% women without a poor obstetric history agreed for an invasive test (P ¼ 0.75).
Discussion
Although USG is not a highly sensitive screening method for detection of aneuploidy, soft markers are detected on USG done for routine malformation scans and/or other obstetric reasons. Sensitivity for each ultrasonographic marker is low (1 to 16%), when observed without associated fetal structural malformations, and most fetuses with such markers have normal outcomes.
1 About 4% of the population can screen positive for fetal chromosomal anomalies with a sensitivity of 75 to 80% when done by an experienced person. 3 In our country, biochemical screening is not being offered to all pregnant women due to various reasons, such as the lack of easy availability, the cost or inadequate awareness among obstetricians. However, ultrasonographic examination of fetuses has become a part of routine antenatal management. Besides being a noninvasive method, it is easily available. Presence of an isolated single soft marker is associated with a variable risk of aneuploidy depending on the marker and mother's age, but it is usually low (1% or less) except for increased nuchal fold thickness, nasal bone hypoplasia and mild ventriculomegaly.
The Society of Obstetricians and Gynecologists of Canada (SOGC) recommends a single 'routine' ultrasound at 16 to 20 weeks in all pregnancies. 18 According to SOGC, the screening ultrasound should evaluate eight markers, five of which (thickened nuchal fold, echogenic bowel, mild ventriculomegaly, echogenic focus in the heart and choroid plexus cyst) are associated with increased risk of fetal aneuploidy, and in some cases with nonchromosomal problems, while three (single umbilical artery, enlarged cisterna magna and pyelectasis) are only associated with increased risk of nonchromosomal abnormalities when seen in isolation.
Identification of soft markers for fetal aneuploidy requires incorporation with other risk factors like maternal age and maternal serum screening results. What makes the decision for an invasive test difficult for the family is the associated risk for fetal loss (0.5%). The risk of aneuploidy perceived by the family may also vary depending on the socioeconomic background, education as well as any past experience regarding such tests. On such a sensitive issue, genetic counseling to the expectant mothers is very important. Different families may interpret the risks differently and may react differently to a similar situation. In our experience, counseling about the screening tests is difficult, as many people do not understand the concept of 'probability'. 19 The obstetric history of a woman is likely to play an important role in the decision regarding the invasive procedure. We had hypothesized that fear of abortion in cases with previous reproductive mishaps could be a factor in decision-making. In spite of the pregnancy being precious, almost 50% of women with poor obstetric history agreed to take risk of amniocentesis rather than Abbreviations: BOH, bad obstetric history; CI, confidence interval; OR, odds ratio. P<0.05 was considered as significant.
Invasive tests on detecting soft markers on USG S Sharda and SR Phadke having an abnormal child. On the other hand, some women who had two or more live children (including one child with some genetic disorder) and primigravidas were reluctant to undergo an invasive procedure. There was no statistically significant difference among the four groups categorized on the basis of previous obstetric history. Similarly, the maternal age and gestational age also did not have any significant effect on decision-making. The single most important factor, which did affect decision, was the type of soft marker detected and its associated risk of aneuploidy. Women were capable of perceiving the high risk of aneuploidy in case of increased nuchal fold thickness and 78% women agreed for amniocentesis in case it was detected. Though the risk for aneuploidy is high in isolated mild ventriculomegaly, only one of the eight cases accepted amniocentesis. Thus, the high level of acceptance in cases with increased nuchal thickening is unlikely to be only due to the increase risk of aneuploidy. We hypothesize that general obstetricians are more aware of increased nuchal thickening as a marker of chromosomal anomaly than other markers and might have stressed the need of amniocentesis.
The information and advice the family has received from their referring obstetrician before coming to a genetics center is likely to be an important factor affecting the decision regarding amniocentesis. We had not collected information about this aspect, and hence could not evaluate the potential role of information bias provided by the primary obstetrician in the decision-making process.
In spite of giving information that a single umbilical artery is not associated with significant risk of chromosomal anomalies, the families with single umbilical artery opted for amniocentesis. This makes it essential to educate obstetricians about soft markers and their risks for chromosomal anomalies. Most of the cases of soft markers will be seen by obstetricians who are more likely to influence the decision about amniocentesis. We give a written summary of the counseling and the risk given to the patient and encourage the family to think for a day and discuss with the obstetrician before deciding about invasive test. Another point that needs to be mentioned is that, in India, obstetricians do not generally practice non-directive counseling, but tend to take a paternalistic approach to advising the patient.
The small number of women studied is one of the biggest limitations of the study, and the possibility of type II error is high. Further, because of the small sample size, we could not feasibly control for the potential confounding or examine interactions between predictors. There also may be other social, psychological or financial factors which may determine the decision about amniocentesis. We have not taken all of these into account. Another limitation and challenge in this arena is the evolving information on these soft markers. As an example, while initial reports regarding the echogenic intracardiac focus had likelihood ratios as high as 6 to 8 for Down's syndrome, more recent reports have found either no increase or smaller likelihood ratios. 15 In a decision analytic model, Caughey et al. 20 concluded that amniocentesis for isolated echogenic intracardiac focus may lead to a high number of fetal losses per Down's syndrome cases detected. Further, higher prevalence of echogenic foci has been reported in Asian women, and the risk of aneuploidy in Asian women with echogenic foci may be still lower. [21] [22] [23] Thus, variation in racial/ethnic prevalence of both the marker and its association with the condition may lead to difficulty in counseling individual patients.
Despite these limitations, we did not identify any obvious effects of maternal age, gestational age or obstetric history on patient decision-making regarding invasive prenatal diagnosis in the setting of a soft ultrasound finding. The type of soft marker and associated risk as perceived by the patient most probably impacts the decision for undertaking an invasive procedure. A future study on a larger population taking into account the issues of psychosocial, economic and religious factors will help us to understand the variability of patients' attitudes and preferences while counseling for soft markers.
